【学会通信 No. 71】 2011. 8. 4
【日本プロテオーム学会通信】は、日本プロテオーム学会会員の皆様に配信しています。

日本プロテオーム学会の皆さま
新潟朱鷺メッセにおける日本プロテオーム学会 2011 大会（大会長山本格教授）は国際色豊かに大盛況のうちに終了し、皆様ご多忙の日々に戻られていることと思います。
このたび International Journal of Proteomics では「Proteomics and Metabolomics in
Gastrointestinal, Hepatobiliary, and Pancreatic Disorders」と題する Special Issue を企画・刊行することになりました。

疾患プロテオミクスでは方法論が急速に進歩し、かつ多様化しています。その技術の臨床応用にあたっては、一つの方法に固執することなく、集学的に考える必要があると思われます。そこで消化器・肝胆膵領域を例として、プロテオミクス、ペプチドミクス、メタボロミクス的アプローチにより、病態の解明、バイオマーカー・治療標的の探索などに関わっておられる様々な立場の方々から広く研究成果を寄せていただくことが企画されました。
Call for Papers を添付いたしましたので、是非ご検討いただきたく、よろしくお願い申し上げます。
平成 23 年 8 月 3 日
千葉大学大学院医学研究院分子病態解析学
千葉大学医学部附属病院検査部・遺伝子診療部・疾患プロテオミクスセンター
野村 文夫
日本プロテオーム学会通信】に対するご意見をメールにてお寄せ下さい(宛先は hirano@yokohama-cu.ac.jp または tomonaga@nibio.go.jp)
ご意見を【日本プロテオーム学会通信】に掲載希望の場合はその旨お知らせ下さい。
【アドレス変更/配信中止】【ご質問・お問合せ】は、日本プロテオーム学会事務局(cljhupo@secretariat.ne.jp)にお願いいたします。

International Journal of Proteomics

Special Issue onProteomics and Metabolomics in Gastrointestinal,
Hepatobiliary, and Pancreatic Disorders
Call for Papers
Mortality due to hepatobiliary and pancreatic malignancies
is high. This is partly because of the late diagnosis oftumors. Colorectal cancer mortality remains one of thehighest among all cancers. Although most screening programs include colonoscopy, it is a general view that useof colonoscopy alone is not practical for a mass screening.
Gastric cancer is the second most common malignancy inthe world.
There is a need for simple and robust risk and tumor
biomarkers for the early identification of people at increased
risk and the early detection of the presence of these tumors,respectively. With the continuing evolution of proteomics
and bioinformatics technologies, clinical proteomics andmetabolomics have shown their potential as a powerful tool
for biomarker discovery.
We invite investigators to contribute original research
articles as well as review articles that deal with development of appropriate disease biomarkers for gastrointestinal,
hepatobiliary, and pancreatic disorders by using proteomic,peptidomic, metabolomic, and modificomic approaches.
Proteome analysis of bile, pancreatic fluid would be ofinterest as well. In addition to direct expression, proteome
analyses of various clinical samples, secretome in culturesand immunoproteomic analysis of the serum antibody
repertoire are welcomed as well.
It should be noted that biomarker discovery by “omic”
approaches is not fruitful without stringent quality controlsof specimens to be analyzed. Therefore, clear and detailed
description on specimen acquisition, handling, and storageis mandatory. Potential topics include, but are not limited to:• Proteome-,

peptidome-, and metabolome-based
biomarkers for the prediction, early detection, andthe evaluation of therapeutic eﬃcacy of cancers,
including potential disease-specific posttranslational
modifications of proteins• Proteome, peptidome, and metabolome findings leading to diagnosis of nonmalignant gastrointestinal,
hepatobiliary, and pancreatic diseases• Application of the latest technologies for the elucida-tion protein signatures of disease, including autoantibodies• Recent progress in the proteomic analyses of humanbile, pancreatic fluid, and liver tissue interstitial fluid• Proteome, peptidome, and metabolome findings dealing with animal models of gastrointestinal, hepatobiliary, and pancreatic diseases• Secretome profiling of human malignant cells
Before submission authors should carefully read over thejournal’s Author Guidelines, which are located at http://www.hindawi.com/journals/ijpro/guidelines/. Prospective authors
should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking Systemat http://mts.hindawi.com/ according to the following
timetable:
Manuscript Due

Friday, 3 February 2012

First Round of Reviews

Friday, 4 May 2012

Publication Date

Friday, 3 August 2012

Lead Guest Editor
Fumio Nomura, Department of Molecular Diagnosis,
Clinical Genetics and Proteomics, Graduate School ofMedicine and Pharmaceutical Science, Chiba University,Chiba, Japan; fnomura@faculty.chiba-u.jp
Guest Editors
Dayan B. Goodenowe, Phenomenome Discoveries Inc.,
Saskatoon, SK, Canada; d.goodenowe@phenomenome.com
Terence C. W. Poon, Faculty of Medicine, Chinese
University of Hong Kong, Hong Kong;tcwpoon@cuhk.edu.hk

Hindawi Publishing Corporation
http://www.hindawi.com/